QURE
uniQure N.V. [QURE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
QURE Stock Summary
Top 10 Correlated ETFs
QURE
Top 10 Correlated Stocks
QURE
In the News
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
uniQure: An FDA Approval, An Advancing Pipeline And A Critical Data Readout
Hemgenix was approved by FDA. uniQure appears undervalued based on the value of milestones and royalties due to the company.
uniQure: Hemgenix Approval Key Catalyst To Move The Needle, Rate Buy
Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49.
uniQure: FDA Approval Achieved, Along With AMT-130 Moving Forward
FDA approval of uniQure N.V.'s Hemgenix for the treatment of adults with Hemophilia B achieved. There is potential to receive European approval of Hemgenix for the treatment of adults with Hemophilia B in 2023 on standard review timeline.
Why Shares of uniQure Rose 14.61% on Wednesday
A big approval for a gene therapy sent the biotech's stock higher.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
The FDA just approved the most expensive drug ever — a hemophilia gene therapy from Carlisle and UniQure — and QURE stock popped Wednesday. The post The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath appeared first on Investor's Business Daily.
uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
uniQure outlicensed AMT-061, EtranaDez, to CSL Behring who will market the gene therapy for hemophilia B. EtranaDez has a PDUFA date in November and if approved, uniQure will collect a $175 m milestone payment upon commercial launch strengthening their cash position.
uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
uniQure N.V. has U.S. and European approvals possible of etranacogene dezaparvovec for treatment of Hemophilia B before end of 2022 and early 2023 respectively. uniQure N.V. has already tapped a partner that is licensed and will help commercialize the drug by the name of CSL Behring.
Why uniQure Stock Is Crashing Today
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
QURE Financial details
QURE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.32 | 0.18 | 0.84 | 11.39 | 2.28 | |
| Net income per share | -2.34 | -3.11 | -2.81 | 7.17 | -2.71 | |
| Operating cash flow per share | -2.13 | -2.47 | -3.03 | 6.26 | -3.1 | |
| Free cash flow per share | -2.25 | -2.63 | -3.25 | 5.88 | -3.48 | |
| Cash per share | 6.59 | 9.44 | 5.51 | 12.1 | 7.55 | |
| Book value per share | 5.04 | 8.08 | 5.49 | 12.96 | 10.19 | |
| Tangible book value per share | 4.88 | 7.93 | 5.4 | 10.99 | 8.38 | |
| Share holders equity per share | 5.04 | 8.08 | 5.49 | 12.96 | 10.19 | |
| Interest debt per share | 1.06 | 1.92 | 1.69 | 3.11 | 3.31 | |
| Market cap | 1.03B | 2.87B | 1.61B | 953.76M | 1.06B | |
| Enterprise value | 827.71M | 2.56B | 1.43B | 533.23M | 974.36M | |
| P/E ratio | -12.33 | -23.08 | -12.85 | 2.89 | -8.36 | |
| Price to sales ratio | 91.03 | 393.68 | 42.83 | 1.82 | 9.95 | |
| POCF ratio | -13.51 | -29.05 | -11.92 | 3.31 | -7.3 | |
| PFCF ratio | -12.79 | -27.21 | -11.13 | 3.53 | -6.51 | |
| P/B Ratio | 5.72 | 8.87 | 6.59 | 1.6 | 2.23 | |
| PTB ratio | 5.72 | 8.87 | 6.59 | 1.6 | 2.23 | |
| EV to sales | 73.35 | 351.82 | 38.2 | 1.02 | 9.15 | |
| Enterprise value over EBITDA | -12.08 | -22.53 | -11.29 | 1.53 | -9.02 | |
| EV to operating cash flow | -10.89 | -25.96 | -10.63 | 1.85 | -6.72 | |
| EV to free cash flow | -10.31 | -24.32 | -9.93 | 1.97 | -5.99 | |
| Earnings yield | -0.08 | -0.04 | -0.08 | 0.35 | -0.12 | |
| Free cash flow yield | -0.08 | -0.04 | -0.09 | 0.28 | -0.15 | |
| Debt to equity | 0.53 | 0.39 | 0.4 | 0.36 | 0.48 | |
| Debt to assets | 0.34 | 0.28 | 0.28 | 0.26 | 0.32 | |
| Net debt to EBITDA | 2.91 | 2.68 | 1.37 | -1.21 | 0.79 | |
| Current ratio | 11.85 | 12.15 | 9.47 | 17.09 | 6.28 | |
| Interest coverage | -40.85 | -31.8 | -32.79 | 41.56 | -12.23 | |
| Income quality | 0.91 | 0.79 | 1.08 | 0.87 | 1.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 6.63 | 13.01 | 3.26 | 0.27 | 1.86 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.01 | 0.11 | 0.12 | |
| Capex to operating cash flow | 0.06 | 0.07 | 0.07 | -0.06 | 0.12 | |
| Capex to revenue | -0.38 | -0.91 | -0.25 | -0.03 | -0.17 | |
| Capex to depreciation | -0.34 | -1 | -0.89 | -2.39 | -2.07 | |
| Stock based compensation to revenue | 0.95 | 2.41 | 0.58 | 0.05 | 0.32 | |
| Graham number | 16.28 | 23.75 | 18.63 | 45.71 | 24.93 | |
| ROIC | 0.44 | 0.39 | 0.72 | -1.01 | -0.59 | |
| Return on tangible assets | -0.31 | -0.28 | -0.37 | 0.46 | -0.2 | |
| Graham Net | 3.95 | 6.32 | 3.45 | 8.41 | 4.37 | |
| Working capital | 216.61M | 352.58M | 231.58M | 591.48M | 400.86M | |
| Tangible asset value | 173.9M | 317.14M | 240M | 505.46M | 391.65M | |
| Net current asset value | 142.28M | 258.63M | 162.42M | 414.84M | 247.82M | |
| Invested capital | 0.2 | 0.23 | 0.29 | 0.23 | 0.3 | |
| Average receivables | 909.5K | 590K | 3.78M | 32.69M | 80.57M | |
| Average payables | 3.35M | 4.74M | 4.73M | 3.14M | 6.74M | |
| Average inventory | 0 | 0 | 0 | 0 | 3.46M | |
| Days sales outstanding | 7.54 | 47.47 | 64.39 | 40.94 | 350.92 | |
| Days payables outstanding | 0 | 0 | 0 | 36.56 | 1.2K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 755.99 | |
| Receivables turnover | 48.43 | 7.69 | 5.67 | 8.92 | 1.04 | |
| Payables turnover | 0 | 0 | 0 | 9.98 | 0.3 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0.48 | |
| ROE | -0.46 | -0.38 | -0.51 | 0.55 | -0.27 | |
| Capex per share | -0.12 | -0.17 | -0.21 | -0.38 | -0.38 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.25 | 0.04 | 0.01 | 0.03 | 2.2 | |
| Net income per share | 0.18 | -1 | -0.84 | -1.02 | 0.15 | |
| Operating cash flow per share | -1.02 | -0.55 | -0.34 | -1.05 | -1.17 | |
| Free cash flow per share | -1.1 | -0.64 | -0.43 | -1.13 | -1.28 | |
| Cash per share | 12.05 | 11.26 | 10.73 | 9.41 | 7.54 | |
| Book value per share | 12.91 | 11.72 | 10.42 | 9 | 10.18 | |
| Tangible book value per share | 10.95 | 9.83 | 8.66 | 7.35 | 8.37 | |
| Share holders equity per share | 12.91 | 11.72 | 10.42 | 9 | 10.18 | |
| Interest debt per share | 2.99 | 2.96 | 3.04 | 3.03 | 3.13 | |
| Market cap | 957.2M | 842.05M | 869.9M | 877.45M | 1.06B | |
| Enterprise value | 536.67M | 452.57M | 508.49M | 575.86M | 975.21M | |
| P/E ratio | 29.15 | -4.51 | -5.57 | -4.58 | 38.94 | |
| Price to sales ratio | 16.59 | 469.89 | 1.75K | 605.56 | 10.32 | |
| POCF ratio | -20.33 | -32.75 | -55.49 | -17.91 | -19.39 | |
| PFCF ratio | -18.9 | -28.29 | -42.94 | -16.56 | -17.75 | |
| P/B Ratio | 1.61 | 1.54 | 1.79 | 2.08 | 2.23 | |
| PTB ratio | 1.61 | 1.54 | 1.79 | 2.08 | 2.23 | |
| EV to sales | 9.3 | 252.55 | 1.02K | 397.42 | 9.49 | |
| Enterprise value over EBITDA | 45.43 | -10.61 | -14.65 | -13.39 | 78.93 | |
| EV to operating cash flow | -11.4 | -17.6 | -32.43 | -11.75 | -17.83 | |
| EV to free cash flow | -10.6 | -15.2 | -25.1 | -10.87 | -16.32 | |
| Earnings yield | 0.01 | -0.06 | -0.04 | -0.05 | 0.01 | |
| Free cash flow yield | -0.05 | -0.04 | -0.02 | -0.06 | -0.06 | |
| Debt to equity | 0.36 | 0.39 | 0.44 | 0.52 | 0.48 | |
| Debt to assets | 0.26 | 0.28 | 0.31 | 0.34 | 0.32 | |
| Net debt to EBITDA | -35.6 | 9.13 | 10.41 | 7.01 | -6.89 | |
| Current ratio | 17.09 | 12.94 | 10.84 | 7.26 | 6.28 | |
| Interest coverage | 0.99 | -21.5 | -20.81 | -19.39 | 7.74 | |
| Income quality | -5.74 | 0.55 | 0.4 | 1.02 | -8.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.73 | 25.11 | 92.94 | 33.17 | 0.57 | |
| Intangibles to total assets | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Capex to operating cash flow | 0.08 | 0.16 | 0.29 | 0.08 | 0.09 | |
| Capex to revenue | -0.06 | -2.26 | -9.21 | -2.75 | -0.05 | |
| Capex to depreciation | -1.92 | -1.91 | -2.31 | -1.89 | -2.17 | |
| Stock based compensation to revenue | 0.12 | 3.83 | 15.72 | 5.25 | 0.12 | |
| Graham number | 7.19 | 16.25 | 14.01 | 14.4 | 5.77 | |
| ROIC | -0.01 | 0.18 | 0.18 | 0.24 | 0.11 | |
| Return on tangible assets | 0.01 | -0.07 | -0.06 | -0.09 | 0.01 | |
| Graham Net | 8.38 | 7.35 | 6.21 | 4.87 | 4.36 | |
| Working capital | 591.48M | 533.51M | 475.04M | 400.6M | 400.86M | |
| Tangible asset value | 505.46M | 458.3M | 404.06M | 343.92M | 391.65M | |
| Net current asset value | 414.84M | 367.06M | 308.58M | 247.51M | 247.82M | |
| Invested capital | 0.23 | 0.25 | 0.29 | 0.33 | 0.3 | |
| Average receivables | 31.27M | 48.71M | 20.88M | 3.36M | 52.99M | |
| Average payables | 3.94M | 6.21M | 9.97M | 8.8M | 9.28M | |
| Average inventory | 0 | 0 | 1.47M | 3.51M | 5.5M | |
| Days sales outstanding | 91.68 | 1.94K | 564.81 | 223.79 | 89.68 | |
| Days payables outstanding | 125.24 | 0 | 1.08K | 790.87 | 599.13 | |
| Days of inventory on hand | 0 | 0 | 319 | 425.96 | 377.67 | |
| Receivables turnover | 0.98 | 0.05 | 0.16 | 0.4 | 1 | |
| Payables turnover | 0.72 | 0 | 0.08 | 0.11 | 0.15 | |
| Inventory turnover | 0 | 0 | 0.28 | 0.21 | 0.24 | |
| ROE | 0.01 | -0.09 | -0.08 | -0.11 | 0.01 | |
| Capex per share | -0.08 | -0.09 | -0.1 | -0.09 | -0.11 |
QURE Frequently Asked Questions
What is uniQure N.V. stock symbol ?
uniQure N.V. is a NL stock and trading under the symbol QURE
Is uniQure N.V. buy or a sell ?
6 stock analysts have 6 predictions with a medium analyst target price of $53.67. The lowest prediction is $34 and the highest is $62
What is QURE stock prediction ?
What is uniQure N.V. stock quote today ?
uniQure N.V. stock price is $19.94 today.
Is uniQure N.V. stock public?
Yes, uniQure N.V. is a publicly traded company.
Company Profile
- Volume Average 559.37K
- Market Capitalization 936.83M
- Employee 463
- CEO Mr. Matthew Craig Kapusta
- Headquarters Amsterdam,NL
- IPO Date 2014-02-05
-
Website
https://www.uniqure.com 
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
